Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Invega Trinza

- PMLiVE

J&J, Lilly and Merck join forces on clinical trials

Will set up database to improve efficiency of industry-sponsored drug trials

- PMLiVE

UCLA’s Eugene Washington joins J&J board

Health policy specialist is also chair of government body to develop comparative effectiveness research programme

- PMLiVE

Xarelto uses extended in US

New FDA approval could be huge sales boost for Bayer's and J&J's anticoagulant

- PMLiVE

Sales rise but profits fall at J&J in Q3

Failed clinical programmes and Synthes acquisition hit net results

- PMLiVE

Janssen unveils €30,000 prize fund for health tech innovation

Will look for 'transformational ideas' in homecare, adherence and personal health management

Janssen adds Astellas JAK inhibitor to its immunology portfolio

Licenses oral rheumatoid arthritis and psoriasis candidate ASP015K

- PMLiVE

Treating the brain with software

Clinical trials of game-like software designed to re-programme the brain and tackle some of the most intractable symptoms of schizophrenia could usher in a new way to treat a range...

European approvals for J&J cancer treatments

EC passes new Dacogen indications and backs subcutaneous Velcade

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

J&J files intravenous Simponi formulation in US

FDA approval would complement J&J’s current subcutaneously-administered product

- PMLiVE

J&J to launch ‘innovation centres’ in US, UK and China

Will target local life sciences partnerships in early-stage innovation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links